Organ systems

Fundus Camera Market to Reach $710.20 Mn, Globally, by 2030 at 4.5% CAGR: Allied Market Research

Retrieved on: 
Monday, September 6, 2021
Vision, Diabetes, Ophthalmology, Organ systems, Fundus photography, Optometry, Blindness, Fundus, Diabetic retinopathy

PORTLAND, Ore., Sept. 6, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, " Fundus Camera Market by Product (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and ROP Fundus Cameras), Portability (Handheld and Tabletop), and End User (Hospitals, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 20212030."

Key Points: 
  • PORTLAND, Ore., Sept. 6, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, " Fundus Camera Market by Product (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and ROP Fundus Cameras), Portability (Handheld and Tabletop), and End User (Hospitals, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 20212030."
  • According to the report, the global fundus camera market generated $445.60 million in 2020, and is expected to garner $710.20 million by 2030, witnessing a CAGR of 4.5% from 2021 to 2030.
  • For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/13448
    Surge in prevalence of chronic eye diseases and favorable government regulations drive the growth of the global fundus camera market.
  • However, high costs of initial investment and lack of awareness in low-income countries hinder the market growth.

Fundus Camera Market to Reach $710.20 Mn, Globally, by 2030 at 4.5% CAGR: Allied Market Research

Retrieved on: 
Monday, September 6, 2021
Vision, Ophthalmology, Diabetes, Organ systems, Fundus photography, Optometry, Blindness, Fundus, Diabetic retinopathy, Retina

PORTLAND, Ore., Sept. 6, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, "Fundus Camera Market by Product (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and ROP Fundus Cameras), Portability (Handheld and Tabletop), and End User (Hospitals, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030." According to the report, the global fundus camera market generated $445.60 million in 2020, and is expected to garner $710.20 million by 2030, witnessing a CAGR of 4.5% from 2021 to 2030.

Key Points: 
  • - Surge in prevalence of chronic eye diseases and favorable government regulations drive the growth of the global fundus camera market.
  • PORTLAND, Ore., Sept. 6, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, " Fundus Camera Market by Product (Mydriatic Fundus Cameras, Non-Mydriatic Fundus Cameras, Hybrid Fundus Cameras, and ROP Fundus Cameras), Portability (Handheld and Tabletop), and End User (Hospitals, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 20212030."
  • According to the report, the global fundus camera market generated $445.60 million in 2020, and is expected to garner $710.20 million by 2030, witnessing a CAGR of 4.5% from 2021 to 2030.
  • For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/13448
    Surge in prevalence of chronic eye diseases and favorable government regulations drive the growth of the global fundus camera market.

Maryann Releases Its New Vitamin C Serum With Hyaluronic Acid

Retrieved on: 
Wednesday, August 4, 2021
Medicine, Organ systems, Dermatology, Skin care, Organic acids, Biomolecules, Acne, Lotion, Hyperpigmentation, Vitamin C

Maryann's Vitamin C serum was developed to treat the areas of skincare that can have the biggest effects on a person's self-confidence: acne scars, hyperpigmentation, and rough texture.

Key Points: 
  • Maryann's Vitamin C serum was developed to treat the areas of skincare that can have the biggest effects on a person's self-confidence: acne scars, hyperpigmentation, and rough texture.
  • For more information on Maryann's Vitamin C Serum or other skincare products, please visit shopmaryann.com .
  • Maryann was founded to give you easy access to premium, natural skincare at an affordable price point.
  • MaryAnn's Vitamin C Serum is infused with Hyaluronic Acid and has a thinner consistency than most lotions, oils, and creams, allowing it to deeply penetrate the outer layers of skin with hydrating nutrients that help boost the skin's cell regeneration and renewal processes.

Dr. Reddy’s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL

Retrieved on: 
Wednesday, August 4, 2021
Health, Pharmaceutical, Nonsteroidal anti-inflammatory drugs, Drugs, Hepatotoxins, Organ systems, Clinical medicine, COX-2 inhibitors, Migraine, Stroke, Celecoxib, Myocardial infarction, Anti-inflammatory, Rofecoxib

Under the terms of agreement, Dr.Reddys will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing.

Key Points: 
  • Under the terms of agreement, Dr.Reddys will receive U.S.$6 million upfront upon closing followed by U.S.$9 million one year from closing.
  • ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults.
  • ELYXYB is an oral solution dosage form which makes it convenient for patients to take it immediately upon emergence of migraine attacks.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

Retrieved on: 
Wednesday, August 4, 2021
FDA, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Organ systems, Hair diseases, Human hair, Organs anatomy), Anatomy, Alopecia areata, Hair loss, Pattern hair loss, Alopecia totalis, Trichoscopy, the Phase 2b/3 ALLEGRO Trial, Alopecia Areata, Pfizer Inflammation & Immunology, THE PHASE 2B/3 ALLEGRO TRIAL, ALOPECIA AREATA, PFIZER INFLAMMATION & IMMUNOLOGY

We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.

Key Points: 
  • We look forward to bringing this potential new treatment option to patients living with alopecia areata as soon as possible.
  • The Phase 2b/3 ALLEGRO trial met the primary efficacy endpoint of improving scalp hair regrowth.
  • All participants entered the study with at least 50 percent scalp hair loss due to alopecia areata, as measured by the Severity of Alopecia Tool (SALT) score.
  • This randomized, placebo-controlled, double-blind study investigated ritlecitinib in patients 12 years of age and older with alopecia areata (n=718).

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Complement deficiency, Organ systems, Medical specialties, Angioedema, Catabasis Pharmaceuticals, Hereditary angioedema, Clinical medicine, Kinin–kallikrein system, Hae, QLS, Kallikrein

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.
  • The session entitled HAE There- Development Landscape in Hereditary Angioedema (HAE) will include an overview of the HAE treatment landscape, information about Catabasiss lead program QLS-215, and a Q&A session.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Organ systems, Health, Autoimmune diseases, Dry eye syndrome, Sjögren syndrome, Visual acuity, Eye, Disease

The prevalence of Dry Eye Disease can significantly impair visual acuity, workplace productivity, and quality of life and increases with age.

Key Points: 
  • The prevalence of Dry Eye Disease can significantly impair visual acuity, workplace productivity, and quality of life and increases with age.
  • Dry Eye Disease is a common condition that occurs when your tears aren't able to provide adequate lubrication for your eyes.
  • Diagnosing Dry Eye Disease is a challenge because its a multifactorial disease with many disparate causes.
  • However, both are non-differential meaning they are screening tests that require follow-up testing because positive results could point to conditions other than Dry Eye Disease.

FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience

Retrieved on: 
Tuesday, August 3, 2021
Complement deficiency, Organ systems, Medical specialties, Hereditary angioedema, Serpinopathies, Clinical medicine, C1-inhibitor, Angioedema, CSL Behring, Hae

"Regardless of being on a preventive therapy or not, being prepared to rapidly treat an HAE attack is of utmost importance.

Key Points: 
  • "Regardless of being on a preventive therapy or not, being prepared to rapidly treat an HAE attack is of utmost importance.
  • BERINERT is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) attacks in adult and pediatric patients.
  • CSL Behring has marketed its C1 Esterase Inhibitor concentrate, BERINERT, in Germany for more than 30 years.
  • Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE.

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Clinical medicine, Organ systems, Neurofibroma, Neurofibromin 1, Antineoplastic drugs, Genodermatoses, MEK inhibitor, Targeted therapy, Neurofibromatosis type I

Hormonal therapies targeting ER, such as SERDs, can be effective in treating ER+ mBC, but over 90% of patients eventually develop resistance to ER-targeted therapy.

Key Points: 
  • Hormonal therapies targeting ER, such as SERDs, can be effective in treating ER+ mBC, but over 90% of patients eventually develop resistance to ER-targeted therapy.
  • We are committed to exploring the full potential of mirdametinib on behalf of patients with devastating cancers and look forward to collaborating with Dr. Rosen and his colleagues at MSK on this important trial.
  • In addition, mirdametinib is being evaluated in a Phase 1b/2 trial in combination with BeiGenes RAF dimer inhibitor, lifirafenib, in patients with advanced or refractory solid tumors harboring RAS mutations, RAF mutations, and other MAPK pathway aberrations.
  • NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Retrieved on: 
Monday, August 2, 2021
Musculoskeletal system, Organ systems, Anatomy, Osteopathies, Skeletal system, Aging-associated diseases, Endocrine diseases, Rheumatology, Osteoporosis, Bone density, Bone, Entera

BOSTON and JERUSALEM, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its poster presentation titled “A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass - An Interim Three-Month Analysis” has been selected by the Program Committee of the American Society for Bone and Mineral Research (ASBMR) for its Annual Meeting scheduled to take place on October 1-4, 2021 in San Diego, California. Dr. Arthur Santora, Entera’s Chief Medical Officer, will present the poster at both the plenary session on October 1 and the general session on October 2, as well as a special session on the Biology of the Aging Skeleton Symposium on September 30.

Key Points: 
  • Three and 6 month results, previously reported by Entera in June 2021 can be found here .
  • Osteoporosis, characterized by low bone mass and deterioration of bone tissue, can lead to decreased bone strength and increased risk of fracture.
  • The Companys most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.